Cell/Gene Tx channel feed

4DMT's in­hal­able gene ther­a­py for cys­tic fi­bro­sis shows ear­ly pos­i­tive signs in tiny group of pa­tients

Last year
R&D

Af­ter gene ther­a­py deaths, Astel­las to re­vis­it fa­tal neu­ro­mus­cu­lar con­di­tion in part­ner­ship with biotech start­up

Last year
Deals
R&D

Bay­er gets its hands on Acuitas' LNP as it lines up first shots at gene edit­ing

Last year
Deals

Ace­po­di­a's off-the-shelf cell ther­a­pies get an­oth­er $100M for on­col­o­gy tri­als

Last year
Financing
Startups

J&J takes vic­to­ry lap on its Carvyk­ti da­ta. But how many pa­tients will take it — and when? #AS­CO23

Last year
R&D

Take­da ax­es gene ther­a­py deal with Po­sei­da Ther­a­peu­tics amid broad­er re­think

Last year
Deals

Pre­ci­sion Bio­Sciences to meet with FDA af­ter tout­ing al­lo­gene­ic CAR-T win

2 years ago
R&D

RA Cap­i­tal-backed non-vi­ral gene ther­a­py start­up Sum­ma­tion Bio to shut down

3 years ago
People

With cash run­ning low, Swedish cell ther­a­py com­pa­ny looks to sell off plat­form

3 years ago
R&D

Out­pace Bio ex­pands cell ther­a­py R&D, nets re­search col­lab­o­ra­tions in Seat­tle

3 years ago
R&D

Rich Hor­gan spear­head­ed a gene ther­a­py for his broth­er. The tri­al end­ed in tragedy, but the work con­tin­ues for more pa­tients

3 years ago
In Focus

UCB en­ters gene ther­a­py space, ink­ing li­cense agree­ment for epilep­sy and neu­rode­gen­er­a­tion re­search

3 years ago
Deals

FDA de­lays Sarep­ta's Duchenne gene ther­a­py de­ci­sion by a month

3 years ago
R&D

PTC cuts gene ther­a­py pro­grams, dis­clos­es PhI­II fail in Friedre­ich's atax­ia and CFO ex­it

3 years ago
R&D

El­e­vate­Bio snags the year's largest raise with $401M Se­ries D, plus a re­search part­ner­ship with No­vo

3 years ago
Financing

In wake of Ru­bius down­fall, a new biotech spin­out launch­es to 'take the next step' in red blood cell ther­a­pies

3 years ago
Startups

No­var­tis beefs up gene ther­a­py pipeline, spend­ing $87.5M on an Avro­bio ther­a­py

3 years ago
Deals
Pharma

First-of-its-kind gene ther­a­py ap­proved for heal­ing wounds in “but­ter­fly chil­dren”

3 years ago
R&D
FDA+

CBER chief Pe­ter Marks to con­sid­er 'al­ter­na­tives' to clin­i­cal holds as they 'put shud­ders down in­vestors' spines'

3 years ago
FDA+

Af­ter rais­ing half a bil­lion dol­lars, a se­cre­tive biotech gives an ear­ly look at its gene edit­ing pipeline

3 years ago
R&D

Pa­tient who re­ceived cus­tom gene ther­a­py like­ly died from im­mune re­ac­tion, not CRISPR, pa­per says

3 years ago
R&D

Mus­tang Bio to sell Mass­a­chu­setts CAR-T man­u­fac­tur­ing fa­cil­i­ty

3 years ago
Deals
Manufacturing

As­traZeneca beefs up cell ther­a­py tool kit with gene edit­ing deal

3 years ago
Deals

Ex­clu­sive: Cell and gene ther­a­py biotech cre­ator Re­play plucks Al­lo­gene CMO Arun Bal­aku­maran to lead clin­i­cal tri­als

3 years ago
People
First page Previous page 18192021222324 Next page Last page
A service from the Financial Times